Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Indiana University
How would you approach a patient with grade 1/2 pancreatic neuroendocrine tumor after progressing on octreotide?
What would be the next line of treatment, PRRT, capecitabine and temozolomide or other?
Answer from: Medical Oncologist at Community Practice
Tem/cape -- responses are good for pancreatic NET. PRRT Is great but so expensive. I’m finding it so hard to get.
Sign in or Register to read more
6227
Related Questions
For patients with rectal cancer being treated along PROSPECT paradigm, would you extrapolate from the IDEA literature and offer 3 months of CAPOX neoadjuvantly, without adjuvant therapy?
What do you recommend for patients with stage 3 MSI-H colorectal cancer who are ineligible for oxaliplatin-based adjuvant therapy?
Would you offer adjuvant 5-FU-based therapy for a patient with adenocarcinoma involving the ischiorectal fossa thought to be tailgut cyst adenocarcinoma who achieved a pCR to 5-FU + RT followed by surgery?
How would you approach a stage II colon cancer with negative ctDNA but markedly elevated CEA level post-colectomy?
How do you dose FOLFOX when given with concurrent chemoradiation in esophageal adenocarcinoma?
For T3N0 rectosigmoid tumors who get surgery upfront, what is your preferred adjuvant therapy?
Would you extrapolate from EMBARK to use an ARPI other than enzalutamide in high risk biochemically recurrent prostate cancer for a patient with contraindications to enzalutamide?
In patients with active IBD and rectal cancer, do you take any precautions before starting TNT?
How do you approach the timing / feasibility of CD38 re-treatment (daratumumab or isatuximab) in a previously CD38-refractory patient with myeloma?
Would you include HER2 directed therapy in the treatment of HER2+ small bowel adenocarcinoma?